Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm to Pursue Major Opportunity in Brain Cancer (ASX:NOX)

Potential for Fundamental Change in the Treatment of Brain Cancer Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most...read more

Netlinkz Announce Australian rollout of the VIN with DI Advisory Services (ASX:NET)

NetLinkz Limited announces expansion of the Australian rollout of the VIN product with Australian Defence Industry Specialists DI Advisory Services NetLinkz Limited (ASX: NET) ('NetLinkz') ...read more

Noxopharm Announce further Data Review Shows Major Clinical Benefits From Veyonda® (ASX:NOX)

Comparative data shows Veyonda® significantly boosts the effectiveness of a promising new form of radiation therapy (177LuPSMA) in advanced prostate cancer 177LuPSMA therapy is the su...read more

Noxopharm Annual Report Captures Positive Progress (ASX:NOX)

Noxopharm Annual Report released today Positive indications for clinical benefits of proprietary drug candidate Veyonda® continue Key commercialisation milestones met Sydne...read more

NetLinkz Limited to establish an IoT Laboratory in Tokyo, Japan (ASX:NET)

NetLinkz Limited to establish an IoT Laboratory in Tokyo, Japan to develop its source code for the Japanese market NetLinkz Limited (ASX: NET) ('NetLinkz ‘or the ‘Company') is p...read more

Noxopharm Announce Veyonda and Radiotherapy Profiled at Key Oncology Meeting (ASX:NOX)

Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meeting Both Noxopharm and independent investigators have abs...read more

Noxopharm Announce Veyonda® Research to be Shared at Two Major Oncology Conferences Enhancing Radiotherapy in Prostate Cancer Treatment (ASX:NOX)

Australian drug development company NoxopharmTM to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas SYDNEY, 12 Sept 201...read more

Novatti Achieves Visa Principal Status (ASX:NOV)

Highlights Granted an Australian Principal Issuing Licence with Visa Revenue generating contracts already signed Circa $300k of additional transaction processing revenue already co...read more

NetLinkz Announce IoT Lab awarded the Innovative Cloud Service Platform (ASX:NET)

Netlinkz Limited is pleased to announce its IoT Lab operated by iSoftStone in Beijing has been awarded the Innovative Cloud Service Platform by the China Software Industry Association NetLinkz Limi...read more

Noxopharm Announce Pre-Clinical Evidence Confirms Veyonda Abscopal Effect (ASX:NOX)

Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effect Pre-clinical...read more

Netlinkz, China Distribution Expansion (ASX:NET)

China Distribution Expansion Netlinkz Ltd is pleased to announces that a Strategic Cooperation Agreement has been signed between Sichuan Meixunda Communications Corporation, a wholly-owned subsid...read more

Noxopharm August 2019 Corporate Presentation (ASX:NOX)

Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today releases its August 2019 Corporate Presentation ahead of Australian and U.S. roadshows. The Presentation ...read more

NetLinkz announce product launch at AWS Summit, Beijing (ASX:NET)

NetLinkz Ltd (ASX: NET) announces the official launch of the first two products from the IoT Lab in Beijing at the AWS (Amazon Web Services) Summit For further information please download the attac...read more

NetLinkz Announce Grant Thornton Australia appointed as a strategic advisor (ASX:NET)

NetLinkz Ltd (ASX: NET) announces it has signed a Memorandum of Understanding to appoint Grant Thornton Australia as a strategic advisor for the Company for corporate advice, product sales and develop...read more

Noxopharm announce Appendix 4C - June 2019 Quarter (ASX:NOX)

Positive results from two prostate cancer trials Phase 2 trial design gaining momentum Investigational New Drug Application to be submitted to FDA in Q3 2019 Pipeline developi...read more

Viewing: 1 - 15 of 200 Previous | Next